Gyre Therapeutics (GYRE) Total Liabilities (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Total Liabilities of $25.0 million for Q1 2026, down 1.8% year-over-year from $25.5 million in Q1 2025, and up 4.95% quarter-over-quarter from $23.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Total Liabilities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Total Liabilities for 17 consecutive years, with $25.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 1.8% year-over-year to $25.0 million; the TTM figure through Mar 2026 stood at $25.0 million (down 1.8% YoY), while the FY2025 annual figure was $23.8 million, down 11.68% from the prior year.
- Total Liabilities improved to $25.0 million in Q1 2026 per GYRE's latest filing, from $23.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $38.1 million in Q4 2023 and bottomed at $1.6 million in Q3 2022.
- Historically, Total Liabilities has averaged $19.4 million across 5 years, with a median of $23.2 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities sank 90.76% — and 2024, when it jumped 315.17%.
- Gyre Therapeutics' Total Liabilities stood at $12.5 million in 2022, then soared by 203.65% to $38.1 million in 2023, then retreated by 29.06% to $27.0 million in 2024, then dropped by 11.68% to $23.8 million in 2025, then gained by 4.95% to $25.0 million in 2026.
- Business Quant data shows GYRE's Total Liabilities at $25.0 million in Q1 2026, $23.8 million in Q4 2025, and $22.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 34.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.34 Mn |
| Mar 31, 2026 | 25.03 Mn |
| Dec 31, 2025 | 23.85 Mn |
| Sep 30, 2025 | 21.97 Mn |
| Jun 30, 2025 | 23.20 Mn |
| Mar 31, 2025 | 25.49 Mn |
| Dec 31, 2024 | 27.00 Mn |
| Sep 30, 2024 | 26.77 Mn |
| Jun 30, 2024 | 27.58 Mn |
| Mar 31, 2024 | 33.24 Mn |
| Dec 31, 2023 | 38.07 Mn |
| Sep 30, 2023 | 6.45 Mn |
| Jun 30, 2023 | 7.40 Mn |
| Mar 31, 2023 | 11.39 Mn |
| Dec 31, 2022 | 12.54 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 4.31 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 14.57 Mn |
| Sep 30, 2021 | 17.80 Mn |